Fresh off its acquisition of full rights to the PD-1 checkpoint inhibitor Libtayo (cemiplimab), Regeneron Pharmaceuticals, Inc. released early data for a costimulatory bispecific antibody that could make certain patients with prostate cancer more amenable to treatment with immunotherapy, and represent an important step for its overall strategy to expand its oncology business.
The drug maker announced the Phase I/II trial data for REGN5678 in advanced metastatic castration-resistant prostate cancer (mCRPC) on 3
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?